The Experts below are selected from a list of 291 Experts worldwide ranked by ideXlab platform
Bernard Czernobilsky - One of the best experts on this subject based on the ideXlab platform.
-
differentiation potential of ovarian Dysgerminoma an immunohistochemical study of 15 cases
Human Pathology, 1995Co-Authors: Beatriz Lifschitzmercer, Heinrich Walt, Ilana Kushnir, Nurit Jacob, Pierre Andre Diener, Roland Moll, Bernard CzernobilskyAbstract:Abstract An immunohistochemical study of 15 ovarian formalin-fixed, paraffin-embedded Dysgerminomas showed positive staining of tumor cells for vimentin in all cases. Ten Dysgerminomas stained for cytokeratin 18. Desmin positivity of single tumor cells was detected in four Dysgerminomas. Glial fibrillary acidic protein was present in two tumors. Prominent human beta chorionic gonadotropin staining was seen in one tumor. S-100 protein was found in two and carcinoembryonic antigen in one of the Dysgerminomas. Placental alkaline phosphatase was present in 12 of the 15 tumors studied. The heterogeneity of the cytoskeletal profile and of other markers showed some similarities to our previously published results on testicular seminomas. Thus, in contrast to previous concepts, dysgeminoma, as is the case with its testicular counterpart the seminoma, appears to be capable of further differentiation, albeit at a primitive level. Our observations also may help to elucidate the relationship between Dysgerminoma and other nonDysgerminomatous ovarian germ cell tumors, and may be of help in the differential diagnosis with poorly differentiated carcinoma, ovarian lymphoma, or other germ cell tumors.
Stephen D Williams - One of the best experts on this subject based on the ideXlab platform.
-
late relapse of ovarian Dysgerminoma case report and literature review
Gynecologic Oncology, 1999Co-Authors: Tanios Bekaiisaab, Lawrence H Einhorn, Stephen D WilliamsAbstract:Dysgerminoma of the ovary is a rare tumor. Ovarian Dysgerminoma is chemosensitive and potentially curable even when in advanced stage. We report a case of intra-abdominal relapse of stage Ia ovarian Dysgerminoma 20 years following initial surgery. The patient was treated with surgical resection followed by a full course of platinum-based chemotherapy. However, she had rapidly progressive disease and eventually died. To date, this is the latest reported case of relapse of ovarian Dysgerminoma. This rare situation has been reported in patients with germ cell tumors of the testis, the male counterpart of ovarian germ cell tumors. Testis cancer patients with late relapse are rarely, if ever, curable by chemotherapy. A diagnosis of recurrent Dysgerminoma should be considered in patients who have the appropriate findings with a history of Dysgerminoma, even if remote. Patients with late recurrences of ovarian germ cell tumors may be less responsive to chemotherapy.
-
chemotherapy of advanced Dysgerminoma trials of the gynecologic oncology group
Journal of Clinical Oncology, 1991Co-Authors: Stephen D Williams, John A Blessing, Kenneth D Hatch, Howard D HomesleyAbstract:Between 1984 and 1989, 20 assessable patients with incompletely resected ovarian Dysgerminoma were treated on two protocols of the Gynecologic Oncology Group (GOG). All patients received cisplatin, bleomycin, and either vinblastine or etoposide. More recent patients also received consolidation chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC). Eleven patients had clinically measurable disease, and 10 responded completely. Fourteen second-look procedures were done, and all were negative. Currently, 19 of 20 patients are disease-free with median follow-up of 26 months. Cisplatin-based chemotherapy is highly effective in patients with advanced Dysgerminoma.
Jean-pierre Droz - One of the best experts on this subject based on the ideXlab platform.
-
cisplatin based chemotherapy in Dysgerminoma of the ovary thirteen year experience at the institut gustave roussy
Gynecologic Oncology, 1995Co-Authors: S Culine, P Duvillard, C Lhomme, J Kattan, G Michel, A Gerbaulet, Jean-pierre DrozAbstract:Abstract Twelve patients with Dysgerminoma of the ovary were treated with various cisplatin-based chemotherapy regimens. Chemotherapy was delivered as primary postoperative treatment in 6 patients. All of them are free of disease 18 to 180 months after initiation of chemotherapy. Six other patients received chemotherapy as part of the salvage treatment for recurrent disease. Three failures were observed: one toxic death, one primary failure, and one subsequent relapse. Three patients remain free of disease 50 to 95 months after initiation of chemotherapy. The role of chemotherapy in early- and advanced-stage Dysgerminoma of the ovary is reviewed.
-
Ovarian Dysgerminoma metastatic to the breast
Gynecologic Oncology, 1992Co-Authors: Kattan J, Jean-pierre Droz, P. Charpentier, Guy Michel, Catherine Lhommé, Arnaud Boutan-laroze, Michel PradeAbstract:Abstract A 16-year-old girl underwent a right salpingo-oophorectomy for a pure Dysgerminoma limited to the right ovary. One month later, she developed a right pelvic mass along with abdominal lymphadenopathies, peritoneal carcinomatosis, left breast mass, and left axillary node. Cytology of the breast mass was suggestive of a pure Dysgerminoma. Breast metastases of epithelial ovarian carcinoma are uncommon. In the literature, this is the first case of a breast metastasis of an ovarian Dysgerminoma.
Laurel W Rice - One of the best experts on this subject based on the ideXlab platform.
-
serum lactic dehydrogenase as a tumor marker in Dysgerminoma
Gynecologic Oncology, 1992Co-Authors: Russell H Pressley, Howard G Muntz, Stephen Falkenberry, Laurel W RiceAbstract:Abstract Dysgerminoma is the most common malignant germ cell tumor in young women. The management of advanced-stage Dysgerminoma challenges the gynecologic oncologist to achieve maximal survival, while maintaining childbearing potential. Radiation therapy has been extremely successful in curing Dysgerminoma, but ovarian conservation is usually not possible. In contrast, various chemotherapeutic regimens have achieved high cure rates with continued ovarian function. Diagnosing recurrent Dysgerminoma promptly so that salvage therapy can be initiated is important when conservative management has been employed. While α-fetoprotein and human chorionic gonadotropin have proven useful as tumor markers in some types of germ cell tumors, they have not been useful in patients with Dysgerminoma. Serum lactic dehydrogenase (LDH) levels are known to be elevated in some patients with Dysgerminoma. We treated a patient with Stage IIIC Dysgerminoma whose initial serum LDH level was markedly elevated. After unilateral salpingo-oophorectomy with pelvic and paraaortic lymphadenectomy, followed by four cycles of VAC chemotherapy, her LDH level returned to normal. Her LDH level rose with disease recurrence and returned to normal again with salvage BEP chemotherapy. This is the first report to document the utility of serial LDH measurements in detecting disease recurrence in patients with ovarian Dysgerminoma.
Juliet Hale - One of the best experts on this subject based on the ideXlab platform.
-
is carboplatin based chemotherapy as effective as cisplatin based chemotherapy in the treatment of advanced stage Dysgerminoma in children adolescents and young adults
Gynecologic Oncology, 2018Co-Authors: Rachana Shah, David M Gershenson, Mark Krailo, James F Amatruda, Suren G Arul, Deborah F Billmire, William E Brady, Allan Covens, Juliet HaleAbstract:Abstract Objective Dysgerminoma is the most common malignant ovarian germ cell tumor (GCT) with peak incidence during adolescence and young adulthood. Current standard of care for patients with disease that has spread outside of the ovary (advanced-stage) utilizes platin-based chemotherapy regimens. The study objective was to compare clinical outcomes between platin-based (carboplatin versus cisplatin) strategies across all age groups (children 25 y) for advanced-stage Dysgerminoma. Methods The Malignant Germ Cell Tumor International Consortium (MaGIC) pooled data from six GCT trials (3 = pediatric, 3 = adult) conducted internationally by pediatric and gynecologic oncology clinical trial organizations (CTOs) between 1983 and 2009. Newly diagnosed patients, with advanced-stage (FIGO IC–IV) Dysgerminoma, who received either carboplatin- or cisplatin-based chemotherapy were eligible for analysis. Results 126 eligible patients were identified; 56 patients (38 = pediatric, 18 = adult) received carboplatin-based and 70 patients (50 = pediatric, 20 = adult) received cisplatin-based chemotherapy. Mean age was 20 y (range = 6–46 y). The median follow-up was 10.3 y (range = 0.17–21.7 y). The five-year event-free survival (EFS 5 ) and overall survival (OS 5 ) was 0.94 (95%CI, 0.88–0.97) and 0.96 (95%CI, 0.91–0.99) respectively. Survival outcomes were comparable between carboplatin-(EFS 5 = 0.96 (95%CI, 0.85–0.99), OS 5 = 0.96 (95%CI, 0.85–0.99)) and cisplatin-(EFS 5 = 0.93 (95%CI, 0.83–0.97), OS 5 = 0.96 (95%CI, 0.87–0.99)) based regimens. Across three age groups, comparison of the EFS 5 ( 25 y = 0.97 (95%CI, 0.81–0.99)) and OS 5 ( 25 y = 0.97 (95%CI, 0.81–0.99)) did not demonstrate any statistically significant differences in outcomes. Conclusions Patients diagnosed with Dysgerminoma have an excellent OS, across all ages, even in the context of metastatic disease. Data from three large CTOs supports the investigation of carboplatin-based regimens in the frontline treatment of all patients with advanced-stage Dysgerminoma to minimize treatment-related toxicities.